SAM
ONCT

Summit Asset Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Summit Asset Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-12
Closed -$24K – 88
2014
Q2 		$24K Sell
12
-2
-14% -$3.96K 0.02% 84
2014
Q1 		$30K Sell
14
-6
-30% -$14.9K 0.02% 84
2013
Q4 		$46K Buy
20
+10
+100% +$22.9K 0.04% 89
2013
Q3 		$29K Hold
10
– – 0.03% 82
2013
Q2 		$95K Buy
+10
New +$77.1K 0.09% 79

Other funds holding ONCT

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Summit Asset Management's ONCT Position: Q3 2014 in Review

Summit Asset Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2014, closing a stake of 12 shares — an estimated $24K sold.

Summit Asset Management first reported a position in ONCT in Q2 2013 and held it in 5 quarters. The position peaked at $95K in Q2 2013. 38 funds tracked by Wall St. Rank hold ONCT as of Q3 2014.

  • Summit Asset Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Summit Asset Management sold 12 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $24K.
  • Summit Asset Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 5 quarters.
  • Summit Asset Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $95K in Q2 2013.
  • 38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2014.

Based on Summit Asset Management's 13F filing for Q3 2014, filed 5 Nov 2014.